Oncorus, Inc. is an early-stage biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses to treat several types of cancer, including highly malignant and aggressive cancers. A leader in corporate philanthropy, Oncorus has taken a pledge to donate a portion of product sales revenue to fund promising cancer research and to support cancer care in the developing world.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
12/19/16	$61,000,000	Series A	Arkin Bio Ventures Astellas Venture Management Celgene Corporation Deerfield Management Company, L.P. Excelyrate Capital Long March Investment Fund MPM Capital	undisclosed
08/21/19	$79,500,000	Series B	Arkin Bio Ventures Astellas Venture Management Celgene Corporation Cowen Healthcare Investments Deerfield Management Company, L.P. IMM Investment MPM Capital Perceptive Advisors QUAD Investment Management Sphera Funds Management Surveyor Capital UBS Oncology Impact Fund	undisclosed